BRD-7552 is primarily used in biochemical and pharmacological research as a selective inhibitor of the bromodomain-containing protein BRD9, which is part of the SWI/SNF chromatin remodeling complex. Its main application lies in studying epigenetic regulation of gene expression, particularly in cancer models where BRD9 activity influences tumor growth and survival. Researchers use BRD-7552 to probe the functional roles of BRD9 in various cellular processes, including differentiation, proliferation, and apoptosis. It has shown potential in preclinical studies for targeting cancers dependent on aberrant chromatin remodeling, especially in synovial sarcoma and acute myeloid leukemia. Due to its specificity, BRD-7552 serves as a valuable tool compound for validating BRD9 as a therapeutic target and for developing more advanced epigenetic drugs.